Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

12    Abbott    $11.5B    up 5.5%
Global revenue: $38.9B (8th); up 10.5%

R&D spend: $3.8B (10th), up 8.6%; 9.8% of rev.

Top brands: Humira ($3.5B), Tricor ($1.3B), Niaspan ($1.2B), AndroGel ($1.1B), Synthroid ($657M)

Planned launches: Bardoxolone (renal), ­elotuzumab (onc.), ­daclizumab (MS)

Promotional spend: $699M (10th); 6.1% of rev.

Patent expirations: Trilipix/Tricor (2013), Niaspan (2013), Humira (2016)

With mega-earner Humira in its back pocket and a dearth of major patent expirations, Abbott seems well-positioned. Sales rose in 2011, and the company saw out-of-US sales take the lead in its revenue portfolio. In an April research note, Jefferies analyst Jeffery Holford called the company a top pick, citing “impressive top-line results” for its all-oral hepatitis C therapy (in Phase IIb) and positive earnings momentum. Abbott also managed to expand its Humira empire when the EU approved the drug to treat ulcerative colitis. Company plans also include dividing into two this year. The changeover will result in a diagnostics/devices firm called Abbott and a research-based pharma company named AbbVie, now up for sale.

Back to first page

Page 12 of 21
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.